![]() Studies show they afflict 1 in 8 women each year and 1 in 5 women over age 65. UTIs are one of the most common infections. Urinary tract infections can happen to both men and women of any age, but are more common in women and girls, who have shorter urethras that are closer to the rectum, making it easier for bacteria to infect the urinary tract. Increasing water intake by 1.5 liters a day keeps UTIs away, study says ” And so this is something that we’ve been dealing with, at the same time when there are increasing numbers of infections that are harder and harder to treat with the drugs that we do have.” Another round will drop out between the second and third phase, typically because companies run out of funds to develop them. “The antibiotic pipeline is what we would call pretty leaky, because, you know, you end up with antibiotics dropping out,” Liu said, meaning many of the drugs don’t make it from the first to second phase of human trials. ![]() Cindy Liu, chief medical officer at the Antibiotic Resistance Action Center at George Washington University. Antibiotic resistant infections kill more than a million people globally each year. A 2021 report from the World Health Organization warned there are not enough new antibiotics in development to overcome the looming threat of antibiotic resistance. New antibiotics are desperately needed because over time, many kinds of bacteria have become resistant to the agents used to treat them. Government investment was needed because new drugs are expensive to develop, and antibiotics tend not to turn large profits. ![]() It was developed in partnership with the US government, as one of 19 projects currently funded by the Biomedical Advanced Research and Development Authority, or BARDA, to combat antimicrobial resistance. Gepotidacin works by blocking enzymes that bacteria need to unzip their DNA – their operating instructions – so they can multiply in the body. So it’s something I’m absolutely delighted about, both from public health and from a company perspective,” said GSK Chief Scientific Officer Tony Wood, on a call with reporters, Thursday.ĭoctors treat female UTIs with wrong antibiotics nearly half the time, study finds “Stopping studies in such circumstances is a pretty rare occurrence in the industry. That’s about a year ahead of the study’s anticipated completion date on the website. GSK said it would prepare its findings for publication in a medical journal and submit its data to the FDA for approval next year. The company said it would follow a recommendation from its independent data monitoring committee to stop the study early because the drug had already proven to be effective. The first new type of antibiotic developed in more than 20 years to treat urinary tract infections (UTIs) appears to be so effective that the pharmaceutical company stopped testing and will soon submit its data to the US Food and Drug Administration for approval.ĭrug company GSK said Thursday the new antibiotic, called gepotidacin, works at least as well as nitrofurantoin, a current front-line medication used to treat UTIs. ![]()
0 Comments
Leave a Reply. |